Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus - associated hemophagocytic lymphohistiocytosis

International Journal of Hematology

Volumn 75, Issue 2, 2002, Pages 174-177

  Imashuku, Shinsaku ^a   Teramura, Tomoko ^a,b   Kuriyama, Kikuko ^b   Kitazawa, Junichi ^c   Ito, Etsuro ^c   Morimoto, Akira ^b   Hibi, Shigeyoshi ^b  

^a Kyoto City Institute of Health and Environmental Sciences   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus; Etoposide; Hemophagocytic lymphohistiocytosis; Therapy related myeloid leukemia

Indexed keywords

ETOPOSIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; RISK ASSESSMENT; ACUTE DISEASE; ADULT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; FOLLOW UP; HISTIOCYTOSIS; INFANT; MALE; MULTICENTER STUDY; MYELOID LEUKEMIA; PRESCHOOL CHILD; SECOND CANCER; VIROLOGY; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT;

EID: 0036463579     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982023     Document Type: Article

References (27)

1. Henter JI, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28:342-347.
2. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood. 1999;93:1869-1874.
3. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19:2665-2673.
4. Pui CH, Ribeiro RC, Hacock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
5. Felice MS, Zubizarreta PA, Chantada GL, et al. Acute myeloid leukemia as a second malignancy: report of 9 pediatric patients in a single institution in Argentina. Med Pediatr Oncol. 1998;30:160-164.
6. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993;11:209-217.
7. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol. 1993;15:99-104.
8. Shearer P, Kapoor G, Beckwith JB, et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. Am J Pediatr Hematol Oncol. 2001;23:109-111.
9. Ng A, Taylor GM, Eden OB. Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause? Pediatr Hematol Oncol. 2000;17:273-279.
10. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 1998;16:3386-3391.
11. Haupt R, Fears TR, Rosso P, et al. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Pediatr Hematol Oncol. 1994;11:499-507.
12. Horibe K, Matsushita T, Numata S, et al. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer. 1993;72:3723-3726.
13. Stine KC, Saylors RL, Sawyer JR, et al. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol. 1997;15:1583-1586.
14. Takahashi T, Yagasaki F, Endo K, et al. Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. Int J Hematol. 1998;68:333-336.
15. Imashuku S, Tabata Y, Teramura T, et al. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Leukemia Lymphoma. 2000;39:37-49.
16. Kitazawa J, Ito E, Arai K, et al. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 2001;37:153-154.
17. Fischer A, Virelizier JL, Arenzana-Seisdedos F, et al. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexatc, and cranial irradiation. Pediatrics. 1985;76:263-268.
18. Loechelt BJ, Egeler M, Filipovich AH, et al. Immunosuppression: preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL). Med Pediatr Oncol. 1994;22:325-328.
19. Chen JS, Lin KH, Lin DT, et al. Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Br J Haematol. 1998;103:756-762.
20. Zhao EG, Song Q, Cross S, et al. Resistance to etoposide-induced apoptosis in a Burkitt's lymphoma cell line. Int J Cancer. 1998;77:755-762.
21. Jarvis WD, Johnson CR, Fornari FA, et al. Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation. J Pharmacol Exp Ther. 1999;290:1384-1392.
22. Uno M, Tsuchiyama J, Moriwaki A, et al. In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol. 2001;113:1009-1014.
23. Chard RLJr, Krivit W, Bleyer WA, et al. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group report. Cancer Treat Rep. 1979;63:1755-1759.
24. Ceci A, de Terlizzi M, Colella R, et al. Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study. Cancer. 1988;62:2528-2531.
25. D'Angio GJ. Langerhans cell histiocytosis and etoposide: risks vs. benefits. Med Pediatr Oncol. 1994;23:69-71.
26. Kikuta H, Sakiyama Y. Etoposide (VP-16) inhibits Epstein-Barr virus determined nuclear antigen (EBNA) synthesis. Br J Haematol. 1995;90:971-973.
27. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412-1417.